Type I interferon and Toll-like receptor expression characterizes inflammatory myopathies
Citation Manager Formats
Make Comment
See Comments
This article requires a subscription to view the full text. If you have a subscription you may use the login form below to view the article. Access to this article can also be purchased.
Abstract
Objectives: Juvenile dermatomyositis (JDM), adult dermatomyositis, and polymyositis (PM) are idiopathic inflammatory myopathies (IIMs) characterized by muscle infiltration and specific muscle fiber alterations. They are thought to have an autoimmune etiology, but triggering factors, and how immunologic attack induces muscle weakness, remain unknown. Recent evidence suggests a key role for type I interferon (IFN)-mediated innate immunity in dermatomyositis, which we explored in JDM, dermatomyositis, and PM by gene expression profiling, and other methods.
Methods: Ten IIM and 5 control muscle biopsies were assessed for expression of approximately 16,000 genes by microarray; 37 additional IIM, 10 dystrophinopathic, and 14 nonmyopathic control muscles were studied for type I IFN-dependent genes, and Toll-like receptor (TLR) expression by immunochemistry and PCR.
Results: Type I IFN-dependent transcripts were significantly upregulated in IIM muscles compared to controls; in JDM the most expressed were ISG15 (408-fold), IFIT3 (261-fold), MX1 (99-fold), and IRF7 (37-fold). IFN-β (but not IFN-α) transcripts were upregulated in PM as well as dermatomyositis/JDM. TLR3 was upregulated particularly in JDM, being localized on vascular endothelial cells, muscle infiltrating cells (mainly myeloid dendritic cells), and regenerating myofibers; TLR7 and TLR9 proteins were present in IIM (prominently in PM), mainly on cell infiltrates, particularly plasma cells, and on some injured myofibers.
Conclusions: IFN-β and type I IFN-induced molecules are involved in PM as well as JDM/dermatomyositis. Endosomal TLRs (effectors of innate immunity) are also involved (but differently) in the 3 conditions, further suggesting viral involvement, although TLR activation could be secondary to tissue damage.
Footnotes
Study funding: Supported by the Italian Ministry of Health 2007–2009 (annual research funding to P.B. and R.M.); the Associazione Volontari Aiuti per la Sclerosi Multipla (RP16 to R.M.); the Fondazione Italiana Sclerosi Multipla (FISM 2009/R/7 to E.M.C.); and the European Union (TOLERAGE HEALTH-F4-2008-202156 to F.Z. and D.B.).
Supplemental data at www.neurology.org
-
- cDNA
- complementary DNA
- DC
- dendritic cells
- DDX58
- DEAD box polypeptide 58
- DEG
- differentially expressed genes
- IFIT1
- interferon-induced protein with tetratricopeptide repeats 1
- IFIT3
- interferon-induced protein with tetratricopeptide repeats 3
- IFN
- interferon
- IgG
- immunoglobulin G
- IIM
- idiopathic inflammatory myopathy
- IRF7
- interferon regulatory factor 7
- ISG15
- 15-kDa interferon-stimulated protein
- ISGF3G
- interferon-stimulated transcription factor 3 gamma
- JDM
- juvenile dermatomyositis
- mDC
- myeloid dendritic cell
- MHCdev
- developmental myosin heavy chain
- MX1
- myxovirus resistance protein 1
- MyD88
- myeloid differentiation primary response gene (88)
- pDC
- plasmacytoid dendritic cell
- PM
- polymyositis
- STAT1
- signal transducer and activator of transcription protein 1
- TLR
- Toll-like receptor
- Received July 6, 2010.
- Accepted February 25, 2011.
- Copyright © 2011 by AAN Enterprises, Inc.
AAN Members
We have changed the login procedure to improve access between AAN.com and the Neurology journals. If you are experiencing issues, please log out of AAN.com and clear history and cookies. (For instructions by browser, please click the instruction pages below). After clearing, choose preferred Journal and select login for AAN Members. You will be redirected to a login page where you can log in with your AAN ID number and password. When you are returned to the Journal, your name should appear at the top right of the page.
AAN Non-Member Subscribers
Purchase access
For assistance, please contact:
AAN Members (800) 879-1960 or (612) 928-6000 (International)
Non-AAN Member subscribers (800) 638-3030 or (301) 223-2300 option 3, select 1 (international)
Sign Up
Information on how to subscribe to Neurology and Neurology: Clinical Practice can be found here
Purchase
Individual access to articles is available through the Add to Cart option on the article page. Access for 1 day (from the computer you are currently using) is US$ 39.00. Pay-per-view content is for the use of the payee only, and content may not be further distributed by print or electronic means. The payee may view, download, and/or print the article for his/her personal, scholarly, research, and educational use. Distributing copies (electronic or otherwise) of the article is not allowed.
Letters: Rapid online correspondence
REQUIREMENTS
You must ensure that your Disclosures have been updated within the previous six months. Please go to our Submission Site to add or update your Disclosure information.
Your co-authors must send a completed Publishing Agreement Form to Neurology Staff (not necessary for the lead/corresponding author as the form below will suffice) before you upload your comment.
If you are responding to a comment that was written about an article you originally authored:
You (and co-authors) do not need to fill out forms or check disclosures as author forms are still valid
and apply to letter.
Submission specifications:
- Submissions must be < 200 words with < 5 references. Reference 1 must be the article on which you are commenting.
- Submissions should not have more than 5 authors. (Exception: original author replies can include all original authors of the article)
- Submit only on articles published within 6 months of issue date.
- Do not be redundant. Read any comments already posted on the article prior to submission.
- Submitted comments are subject to editing and editor review prior to posting.
You May Also be Interested in
Dr. David Beversdorf and Dr. Ryan Townley
► Watch
Topics Discussed
Alert Me
Recommended articles
-
Article
Sarcoplasmic MxA expressionA valuable marker of dermatomyositisAkinori Uruha, Atsuko Nishikawa, Rie S. Tsuburaya et al.Neurology, December 30, 2016 -
Article
Naive CD4 T-cell activation identifies MS patients having rapid transition to progressive MSEvelyn Zastepa, Leslie Fitz-Gerald, Michael Hallett et al.Neurology, January 22, 2014 -
Views & Reviews
Proposed immunologic models of the inflammatory myopathies and potential therapeutic implicationsSteven A. Greenberg et al.Neurology, October 10, 2007 -
Article
Inflammatory myopathy with myasthenia gravisThymoma association and polymyositis pathologyNaohiro Uchio, Kenichiro Taira, Chiseko Ikenaga et al.Neurology: Neuroimmunology & Neuroinflammation, December 24, 2018